Clinical trials data
Trail Making Test in Parkinson's disease trials: 156 registered studies
Every registered Parkinson's disease study on ClinicalTrials.gov that names the Trail Making Test in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered Parkinson's disease studies name it in an outcome measure
- 156
- Name it in a primary outcome, 24%
- 38 of 156
Tests named in the same studies
- 1
Stroop Color-Word Test68 studies, 19 as a primary outcome
- 2
Verbal Fluency50 studies, 10 as a primary outcome
- 3
Digit Span Test42 studies, 8 as a primary outcome
- 4
Verbal Learning32 studies, 12 as a primary outcome
- 5
Symbol Coding20 studies, 6 as a primary outcome
- 6
Category Fluency19 studies, 5 as a primary outcome
- 7
Picture Naming Test16 studies, 3 as a primary outcome
- 8
Complex Figure Copy and Recall13 studies, 2 as a primary outcome
- 9
Line Angle Matching12 studies, 3 as a primary outcome
- 10
Card Sorting Test (Berg)11 studies, 3 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 3 | 0 |
| 2012 | 3 | 2 |
| 2013 | 4 | 1 |
| 2014 | 4 | 0 |
| 2015 | 5 | 0 |
| 2016 | 4 | 0 |
| 2017 | 9 | 2 |
| 2018 | 6 | 3 |
| 2019 | 12 | 2 |
| 2020 | 9 | 4 |
| 2021 | 16 | 6 |
| 2022 | 15 | 3 |
| 2023 | 14 | 4 |
| 2024 | 14 | 4 |
| 2025 | 12 | 3 |
| 2026 | 24 | 4 |
Phases and study sizes
By phase
- Early phase 12 studies, 0 as a primary outcome
- Phase 16 studies, 0 as a primary outcome
- Phase 1/24 studies, 2 as a primary outcome
- Phase 28 studies, 1 as a primary outcome
- Phase 44 studies, 0 as a primary outcome
- Not applicable116 studies, 29 as a primary outcome
- Observational16 studies, 6 as a primary outcome
Participants per study
- Not applicable39 median, 24 to 60
- Observational73 median, 48 to 223
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 115 | 39 | 24 to 60 |
| Observational | 16 | 73 | 48 to 223 |
When Parkinson's disease trials measure it
Latest time point of each outcome
- Within a day20 outcomes, 9 as a primary outcome
- Up to 4 weeks27 outcomes, 6 as a primary outcome
- 1 to 3 months53 outcomes, 12 as a primary outcome
- 3 to 6 months25 outcomes, 7 as a primary outcome
- 6 to 12 months16 outcomes, 2 as a primary outcome
- 1 to 2 years5 outcomes, 0 as a primary outcome
- Over 2 years3 outcomes, 0 as a primary outcome
- No duration given7 outcomes, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
149 of the 156 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting31 studies, 9 as a primary outcome
- Not yet recruiting12 studies, 1 as a primary outcome
- Active, not recruiting2 studies, 0 as a primary outcome
- Completed57 studies, 18 as a primary outcome
- Stopped early13 studies, 3 as a primary outcome
- Status unknown41 studies, 7 as a primary outcome
What they test
- Behavioral44 studies, 12 as a primary outcome
- Drug20 studies, 3 as a primary outcome
- Device39 studies, 3 as a primary outcome
- Dietary supplement2 studies, 0 as a primary outcome
- Procedure7 studies, 2 as a primary outcome
- Diagnostic test2 studies, 1 as a primary outcome
- Biological2 studies, 0 as a primary outcome
- Radiation1 studies, 1 as a primary outcome
- Genetic2 studies, 1 as a primary outcome
- Other62 studies, 18 as a primary outcome
- None given5 studies, 2 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States44 studies, 15 as a primary outcome
- Italy20 studies, 4 as a primary outcome
- Spain9 studies, 3 as a primary outcome
- Netherlands8 studies, 1 as a primary outcome
- Sweden8 studies, 1 as a primary outcome
- Brazil7 studies, 1 as a primary outcome
- Canada7 studies, 1 as a primary outcome
- Taiwan7 studies, 5 as a primary outcome
- Türkiye7 studies, 3 as a primary outcome
- Switzerland6 studies, 1 as a primary outcome
- China5 studies, 2 as a primary outcome
- Germany5 studies, 0 as a primary outcome
26 countries in all. A study with sites in several counts in each; 12 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed Parkinson's disease studies that name the Trail Making Test: 24 of 57, 42%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed Parkinson's disease studies that name the Trail Making Test | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 6, 11% | 776, 10% |
| Results on ClinicalTrials.gov only | 7, 12% | 1,139, 14% |
| A results paper only | 11, 19% | 1,711, 22% |
| Neither | 33, 58% | 4,327, 54% |
The 156 studies
156 studies match. 38 name the Trail Making Test in a primary outcome. Median size 40 participants. Median time to the primary outcome: 6 weeks.
Loading 156 studies; the filters turn on when they arrive.
2026 is partly planned starts. Not shown: 1 with no start year.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 3 | 0 |
| 2012 | 3 | 2 |
| 2013 | 4 | 1 |
| 2014 | 4 | 0 |
| 2015 | 5 | 0 |
| 2016 | 4 | 0 |
| 2017 | 9 | 2 |
| 2018 | 6 | 3 |
| 2019 | 12 | 2 |
| 2020 | 9 | 4 |
| 2021 | 16 | 6 |
| 2022 | 15 | 3 |
| 2023 | 14 | 4 |
| 2024 | 14 | 4 |
| 2025 | 12 | 3 |
| 2026 | 24 | 4 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 4, other 152. Interventional 140, observational 16.
As a primary outcomeSecondary or other outcomeThe Trail Making Test
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07907718 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants50 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07865260 | Start2026 | PhaseNot applicable | ConditionsMild cognitive impairment, Stroke, Parkinson's disease | Participants80 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07833748 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants12 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07718659 | Start2026 | PhasePhase 1 | ConditionsParkinson's disease | Participants8 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07714772 | Start2026 | PhaseObservational | ConditionsParkinson's disease, Sleep and sleep disorders | Participants50 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07705373 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants200 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07678983 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants66 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07641569 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants39 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07641556 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07636538 | Start2026 | PhaseNot applicable | ConditionsMild cognitive impairment, Stroke, Parkinson's disease | Participants30 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07630194 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants90 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07616050 | Start2026 | PhaseNot applicable | ConditionsMild cognitive impairment, Stroke, Parkinson's disease, Multiple sclerosis, Aging, frailty and exercise | Participants70 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07582497 | Start2026 | PhaseNot applicable | ConditionsStroke, Parkinson's disease | Participants60 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07569120 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease, Healthy volunteers, Aging, frailty and exercise | Participants165 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07518290 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants98 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07478146 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07463755 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants36 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07440563 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07355842 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease, Sleep and sleep disorders | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07340073 | Start2026 | PhasePhase 1 | ConditionsParkinson's disease | Participants24 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07271927 | Start2025 | PhaseNot applicable | ConditionsParkinson's disease | Participants15 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07262658 | Start2022 | PhaseObservational | ConditionsParkinson's disease | Participants40 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07240272 | Start2023 | PhaseNot applicable | ConditionsParkinson's disease | Participants28 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07221994 | Start2025 | PhaseNot applicable | ConditionsParkinson's disease | Participants3 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07214974 | Start2026 | PhaseEarly phase 1 | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease | Participants600 | Lead sponsorIndustry | StatusNot yet recruiting | Library tests named
|
Questions, answered from the data
How many Parkinson's disease trials use the Trail Making Test?
156 registered Parkinson's disease studies on ClinicalTrials.gov name it in an outcome measure, 38 of them in a primary outcome: 17% of the condition's 892 studies with a cognitive outcome, against 14% of all of them. It is the test Parkinson's disease trials name most.
Which tests do Parkinson's disease trials use with the Trail Making Test?
The Stroop Color-Word Test (68 studies), Verbal Fluency (50 studies) and the Digit Span Test (42 studies).
When do Parkinson's disease trials measure the Trail Making Test?
Half of the primary outcomes that name the Trail Making Test are measured within 6 weeks of the start, and the middle half from 2 days to 13 weeks. 36 primary outcomes give a duration.
How many completed Parkinson's disease trials that use the Trail Making Test have reported results?
24 of the 57 completed studies that name it, 42%, have reported results: 13 posted them on ClinicalTrials.gov, 17 have a results paper linked to the registry record, and 6 did both. The other 33 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Trail Making Test A and Trail Making Test B as one test family, so this page counts their studies together.
Run the Trail Making Test in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.